Lower drug prices could eliminate coverage gap in Medicare prescription...( ket because drug companies wouldn't be ...),Health

The researchers compared the average wholesale price of 30 drugs from the United States that are also sold in other countries. They calculated the cost of pharmaceutical drugs at average wholesale price and at a 20 percent discount, which is approximately the discount negotiated with the pharmaceutical companies by private insurers administering the Medicare drug benefit. Compared to U.S. drug prices, the prices were 52 percent lower in Canada, 59 percent lower in France and 47 percent lower in the United Kingdom. The researchers said these countries provide a benchmark for the drug prices Medicare could achieve. If Medicare could meet this same benchmark, then the coverage gap could be eliminated.

The authors created two models to simulate prescription drug spending in 2006. The first model mirrored the recently passed prescription drug plan. The second model was identical to the first, with the exception that it included a 45 percent drug price discount. In this model, the coverage plan hole was closed. Using the first model, drug spending would be $101.9 billion, whereas, under the second model, total spending in 2006 would be $73.6 billion. More than $44 billion would be financed by Medicare in both models, indicating that Medicare spending would not increase.

In order to reduce individual spending by Medicare participants, the United States would have to negotiate with drug companies to lower prices. However, the current prescription drug legislation has a provision that restricts the federal government from negotiating prices with drug companies. The potential trade-off, according to Dr. Anderson and his colleagues, is a loss of pharmaceutical research and development of new drugs. U.S. manufacturers produce nearly half of the major drugs marketed worldwide and a change in their profits may also affect investment into the industry
'"/>

Contact: Kenna L. Lowe
paffairs@jhsph.edu
410-955-6878
Johns Hopkins University Bloomberg School of Public Health
21-Jul-2004